Table 2 Therapy regimens of patients with gastric cancer according to age at diagnosis
Variables | ≤ 44 years | 45–64 years | 65–74 years | ≥ 75 years | Total | P value |
|---|---|---|---|---|---|---|
Neoadjuvant therapy regimens | 284 | 1924 | 1049 | 122 | 3379 | < 0.001 |
 Fluorouracil and platinum-based | 108 (38.03) | 833 (43.30) | 511 (48.71) | 65 (53.28) | 1517 (44.89) |  |
 Taxane-based chemotherapy | 15 (5.28) | 102 (5.30) | 39 (3.72) | 6 (4.92) | 162 (4.79) |  |
 Triplet chemotherapy | 100 (35.21) | 560 (29.11) | 217 (20.69) | 15 (12.30) | 892 (26.40) |  |
 Immunotherapy ± chemotherapy | 36 (12.68) | 263 (13.67) | 177 (16.87) | 16 (13.11) | 492 (14.56) |  |
 anti-HER2 therapy and chemotherapy | 6 (2.11) | 63 (3.27) | 29 (2.76) | 3 (2.46) | 101 (2.99) |  |
 Others | 19 (6.69) | 103 (5.35) | 76 (7.24) | 17 (13.93) | 215 (6.36) |  |
Adjuvant therapy regimens | 4130 | 28,408 | 15,602 | 2717 | 50,857 | < 0.001 |
 Fluorouracil and platinum-based | 2159 (52.28) | 14,936 (52.58) | 7378 (47.29) | 715 (26.32) | 25,188 (49.53) |  |
 5-FU | 605 (14.65) | 5317 (18.72) | 4047 (25.94) | 1468 (54.03) | 11,437 (22.49) |  |
 Taxane-based chemotherapy | 311 (7.53) | 1662 (5.85) | 796 (5.10) | 73 (2.69) | 2842 (5.59) |  |
 Triplet chemotherapy | 395 (9.56) | 2142 (7.54) | 773 (4.95) | 44 (1.62) | 3354 (6.59) |  |
 Immunotherapy ± chemotherapy | 268 (6.49) | 1376 (4.84) | 802 (5.14) | 97 (3.57) | 2543 (5.00) |  |
 anti-HER2 therapy and chemotherapy | 49 (1.19) | 300 (1.06) | 152 (0.97) | 20 (0.74) | 521 (1.02) |  |
 Others | 343 (8.31) | 2675 (9.42) | 1654 (10.60) | 300 (11.04) | 4972 (9.78) |  |
First-line therapy regimens | 5456 | 27,641 | 15,347 | 3403 | 51,847 | < 0.001 |
 anti-HER2 therapy and chemotherapy | 243 (4.45) | 1214 (4.39) | 780 (5.08) | 191 (5.61) | 2428 (4.68) |  |
 Immunotherapy ± chemotherapy | 1054 (19.32) | 4326 (15.65) | 2431 (15.84) | 574 (16.87) | 8385 (16.17) |  |
 Fluorouracil and platinum-based | 1498 (27.46) | 8915 (32.25) | 5009 (32.64) | 699 (20.54) | 16,121 (31.09) |  |
 5-FU | 592 (10.85) | 3920 (14.18) | 2840 (18.51) | 1185 (34.82) | 8537 (16.47) |  |
 Taxane-based | 961 (17.61) | 4274 (15.46) | 1972 (12.85) | 301 (8.85) | 7508 (14.48) |  |
 Triplet chemotherapy | 495 (9.07) | 1941 (7.02) | 840 (5.47) | 122 (3.59) | 3398 (6.55) |  |
 others | 613 (11.24) | 3051 (11.04) | 1475 (9.61) | 331 (9.73) | 5470 (10.55) |  |
Second-line therapy regimens | 955 | 3956 | 1602 | 257 | 6770 | < 0.001 |
 anti-HER2 and chemotherapy | 53 (5.55) | 231 (5.84) | 122 (7.62) | 26 (10.12) | 432 (6.38) |  |
 Immunotherapy ± chemotherapy | 233 (24.4) | 898 (22.7) | 388 (24.22) | 57 (22.18) | 1576 (23.28) |  |
 anti-VEGF | 59 (6.18) | 313 (7.91) | 132 (8.24) | 25 (9.73) | 529 (7.81) |  |
 Chemotherapy and anti-VEGF | 185 (19.37) | 725 (18.33) | 271 (16.92) | 43 (16.73) | 1224 (18.08) |  |
 Taxane-based | 271 (28.38) | 1133 (28.64) | 419 (26.15) | 50 (19.46) | 1873 (27.67) |  |
 5-FU | 32 (3.35) | 173 (4.37) | 87 (5.43) | 19 (7.39) | 311 (4.59) |  |
 Fluorouracil-based and platinum-based | 49 (5.13) | 240 (6.07) | 86 (5.37) | 15 (5.84) | 390 (5.76) |  |
 Triplet chemotherapy | 61 (6.39) | 190 (4.80) | 64 (4.00) | 12 (4.67) | 327 (4.83) |  |
 others | 12 (1.26) | 53 (1.34) | 33 (2.06) | 10 (3.89) | 108 (1.60) |  |